{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:43:30Z","timestamp":1794411810105,"version":"4.9.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2002,4]]},"DOI":"10.1016\/s0002-9394(02)01327-2","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T07:42:39Z","timestamp":1027582959000},"page":"467-474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":139,"title":["A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with aids"],"prefix":"10.1016","volume":"133","member":"78","reference":[{"key":"10.1016\/S0002-9394(02)01327-2_BIB1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1128\/AAC.37.9.1945","article-title":"Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region","volume":"37","author":"Azad","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/oli.1.1996.6.145","article-title":"Proof of mechanism of antisense drugs","volume":"6","author":"Crooke","year":"1996","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0166-3542(95)00035-K","article-title":"Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs","volume":"28","author":"Azad","year":"1995","journal-title":"Antiviral Research"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB5","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1128\/AAC.40.9.2004","article-title":"Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA","volume":"40","author":"Anderson","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB6","first-page":"163","article-title":"Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides","volume":"42","author":"Detrick","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB7","series-title":"Antisense drug technology principles, strategies, and applications","first-page":"725","article-title":"The development of antisense oligonucleotides as antivirals","author":"Grillone","year":"2001"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1076\/ocii.7.3.189.4007","article-title":"Fomivirsen\u2014a phosphorothioate oligonucleotide for the treatment of CMV retinitis","volume":"7","author":"De Smet","year":"1999","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/168.3.557","article-title":"A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group","volume":"168","author":"Spector","year":"1993","journal-title":"J Infect Dis"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.7326\/0003-4819-115-9-665","article-title":"A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS","volume":"115","author":"Palestine","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB11","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-126-4-199702150-00002","article-title":"Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS","volume":"126","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-126-4-199702150-00001","article-title":"Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized controlled trial","volume":"126","author":"Lalezari","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB13","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/archopht.1994.01090240037023","article-title":"Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial","volume":"112","author":"Martin","year":"1994","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB14","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/archopht.1989.01070020841024","article-title":"A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Study Group","volume":"107","author":"Holland","year":"1989","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB15","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/bmj.317.7168.1301","article-title":"Randomization methods in controlled trials","volume":"317","author":"Roberts","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB16","first-page":"475","article-title":"Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS","volume":"133","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB17","first-page":"484","article-title":"Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS","volume":"133","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB18","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1002\/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W","article-title":"The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting","volume":"53","author":"Mor","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB19","series-title":"Ocular infection and immunology","first-page":"1088","article-title":"Cytomegalovirus diseases","author":"Holland","year":"1996"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB20","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1553-2712.1999.tb00165.x","article-title":"Statistical methodology","volume":"6","author":"Young","year":"1999","journal-title":"Acad Emerg Med"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB21","series-title":"Analysis of survival data","author":"Cox","year":"1984"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB22","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/archopht.1996.01100140007001","article-title":"Assessment of cytomegalovirus retinitis. Clinical evaluation versus centralized grading of fundus photographs","volume":"114","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1076\/ocii.7.3.231.4008","article-title":"CMV retinitis in the era of HAART","volume":"7","author":"Cassoux","year":"1999","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB24","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/00002030-200006160-00013","article-title":"Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy","volume":"14","author":"Deayton","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/eye.1999.76","article-title":"Changing trends in cytomegalovirus retinitis with highly active anti-retroviral therapy (HAART)","volume":"13","author":"Dhillon","year":"1999","journal-title":"Eye"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB26","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1086\/515281","article-title":"Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy","volume":"177","author":"Macdonald","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0002-9394(98)00134-2","article-title":"Cytomegalovirus retinitis and viral resistance","volume":"126","author":"Jabs","year":"1998","journal-title":"Am J Ophthalmol."},{"key":"10.1016\/S0002-9394(02)01327-2_BIB28","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/514249","article-title":"Cytomegalovirus retinitis and viral resistance","volume":"177","author":"Jabs","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1386-6532(99)00031-1","article-title":"Ganciclovir resistance and UL97 gene mutations in cytomegalovirus blood isolates from patients with AIDS treated with ganciclovir","volume":"13","author":"Abraham","year":"1999","journal-title":"J Clin Virol"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1076\/ocii.7.3.179.4000","article-title":"New strategies for the management of AIDS-related CMV retinitis in the era of potent antiretroviral therapy","volume":"7","author":"Holland","year":"1999","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB31","first-page":"670","article-title":"Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys","volume":"26","author":"Leeds","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB32","first-page":"329","article-title":"Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy","volume":"127","author":"Martin","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/S0002-9394(02)01327-2_BIB33","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1056\/NEJM199904083401402","article-title":"Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group","volume":"340","author":"Martin","year":"1999","journal-title":"N Engl J Med"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939402013272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939402013272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T12:28:42Z","timestamp":1757593722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939402013272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["S0002939402013272"],"URL":"https:\/\/doi.org\/10.1016\/s0002-9394(02)01327-2","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2002,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with aids","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0002-9394(02)01327-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 Elsevier Science Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}